financetom
Business
financetom
/
Business
/
RBC on CGI Acquiring Daugherty
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
RBC on CGI Acquiring Daugherty
Dec 12, 2024 9:02 AM

11:38 AM EST, 12/12/2024 (MT Newswires) -- CGI announced after market close on Wednesday that it had signed an equity purchase agreement to acquire Daugherty, a St. Louis-based professional services firm serving Fortune 500 customers in financial services, healthcare, communications, and retail and manufacturing. Daugherty specializes in AI, data analytics, strategic IT consulting, and business advisory services. The transaction is expected to close in Q1/FY25 (December). CGI did not disclose any financial details.

RBC, which is Neutral on the tuck-in acquisition, estimates that CGI paid US$275 million for Daugherty which it calculates generates US$250 million annual revenue. The Daugherty acquisition is also estimated to be 2% accretive to CGI's annual adj. EPS, RBC said.

CGI is rated Outperform, with a $178 target.

Price: 161.38, Change: -0.95, Percent Change: -0.59

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Relay Therapeutics to Collaborate With Pfizer to Evaluate Metastatic Breast Cancer Treatment
Relay Therapeutics to Collaborate With Pfizer to Evaluate Metastatic Breast Cancer Treatment
Jun 5, 2024
05:04 PM EDT, 06/05/2024 (MT Newswires) -- Relay Therapeutics ( RLAY ) unveiled late Wednesday a clinical trial collaboration with Pfizer ( PFE ) to evaluate a treatment for patients with PI3Ka-mutated, HR+, HER2- metastatic breast cancer. The partnership is evaluating atirmociclib, Pfizer's ( PFE ) investigative selective-CDK4 inhibitor, in combination with RLY-2608 and fulvestrant, Relay Therapeutics ( RLAY )...
Ventyx Biosciences Preclinical Study of Obesity Control Candidate Shows Positive Results
Ventyx Biosciences Preclinical Study of Obesity Control Candidate Shows Positive Results
Jun 5, 2024
05:04 PM EDT, 06/05/2024 (MT Newswires) -- Ventyx Biosciences ( VTYX ) said Wednesday that VTX3232 effectively reduced body weight and food intake during two preclinical diet-induced obesity mouse model studies. The results show that the drug decreased liver steatosis and triglycerides, and also had greater benefits in combination with semaglutide, according to the company. The company said it plans...
Gentherm Authorizes New $150 Million Stock Buyback Program
Gentherm Authorizes New $150 Million Stock Buyback Program
Jun 5, 2024
05:00 PM EDT, 06/05/2024 (MT Newswires) -- Gentherm ( THRM ) said late Wednesday its board has authorized a new $150 million stock buyback program. The new program will take effect as soon as the auto parts and medical device company exhausts the $26 million remaining under its existing share repurchase plan that began in 2020, Gentherm ( THRM )...
Thermo Fisher Scientific Insider Sold Shares Worth $11,374,358, According to a Recent SEC Filing
Thermo Fisher Scientific Insider Sold Shares Worth $11,374,358, According to a Recent SEC Filing
Jun 5, 2024
05:05 PM EDT, 06/05/2024 (MT Newswires) -- Marc N Casper, Director, Chairman & CEO, on June 03, 2024, sold 20,000 shares in Thermo Fisher Scientific ( TMO ) for $11,374,358. Following the Form 4 filing with the SEC, Casper has control over a total of 183,724 shares of the company, with 123,816 shares held directly and 59,908 controlled indirectly. SEC...
Copyright 2023-2026 - www.financetom.com All Rights Reserved